Market reactionShares fell 21% on Nov 4.
Cullinan Therapeutics is a clinical-stage company developing zipalertinib, with partner Taiho, for lung cancer with EGFR exon 20 insertion mutations; it is under FDA review and not yet approved.
Cullinan's investment case combines zipalertinib's two approval routes with a developing T cell engager pipeline. Second-line monotherapy remains under FDA review, with a February 27, 2027 target decision; first-line combination submission has started, with completion expected by year-end 2026. Randomized progression-free survival benefit supports the first-line opportunity. CLN-049 has begun a potentially registrational Phase 2 AML study. Velinotamig's cleared autoimmune cytopenia study broadens development beyond cancer, with safety and disease activity central to its next clinical assessment.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: First-line application is completed and accepted
Does Cullinan complete the first-line combination application as guided, and does FDA subsequently accept it?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Zipalertinib approval routes advance; velinotamig broadens Cullinan's autoimmune pipeline
REZILIENT3 delivers Phase 3 PFS win, but the 2L NDA rides single-arm data to a Feb 2027 PDUFA — approvability of that filing is the first gate
Zipalertinib NDA pending at FDA with Phase 3 first-line win in hand; approvability on single-arm accelerated approval data is the make-or-break condition
Zipalertinib's FDA decision will determine whether Cullinan can establish a commercial oncology franchise in EGFR ex20ins NSCLC ahead of a crowded next-generation TKI field
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Zipalertinib
Disease areas: Blood cancers, Lung cancer, Kidney diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
12 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.